161Tb-PSMA-617 was significantly moreeffective in reducing the tumor-cell viability (determined by MTT assays) andsurvival (determined by clonogenic assays) as compared to177Lu-PSMA-617 when applied at activityconcentrations in the range of 0.1–10 MBq/mL (p < 0.05) and 0.05–5.0 MBq/mL (p < 0.05) respectively (Fig. 1a/b). The gene discussed is FOLH1; the disease is neoplasm.